Search
Azilsartan medoxomil
go.drugbank.com/drugs/DB08822ApprovedInvestigationalIt is also available in a combination product with [chlorthalidone]. … It is a selective AT1 subtype angiotensin II receptor antagonist. Azilsartan medoxomil is a relatively recently-developed antihypertensive drug that was first approved by the FDA in February 2011.
Tetraethylammonium
go.drugbank.com/drugs/DB08837InvestigationalThe only marketed drug containing tetraethylammonium was a combination drug called Fosglutamina B6, but this drug has now been discontinued. … The most common use of tetraethylammonium presently is as a pharmacological research agent that blocks selective potassium channels.
Fingolimod
go.drugbank.com/drugs/DB08868ApprovedInvestigational[A176474] Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. … Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects.
Cabozantinib
go.drugbank.com/drugs/DB08875ApprovedInvestigationalCabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. … [L15123] In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formulation gained additional approval in both the US and Canada in 2019
Categories: Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexMirabegron
go.drugbank.com/drugs/DB08893ApprovedInvestigationalMirabegron is a sympathomimetic beta-3 adrenergic receptor agonist used to relax the smooth muscle of the bladder in the treatment of urinary frequency and incontinence. … Mirabegron has a comparatively favorable adverse effect profile as compared to other available treatment options, and its complementary mechanism to the antimuscarinics that came before it allows for its
Ponatinib
go.drugbank.com/drugs/DB08901ApprovedInvestigationalPonatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic IndexCanagliflozin
go.drugbank.com/drugs/DB08907ApprovedInvestigationalCanagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise … It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 for a second indication of reducing the risk of cardiovascular events in patients diagnosed with type
Iodamide
go.drugbank.com/drugs/DB08948ApprovedWithdrawnIodamide is a contrast medium molecule that is no longer marketed in the United States.
Categories: Compounds used in a research, industrial, or household settingIndoramin
go.drugbank.com/drugs/DB08950ApprovedWithdrawnIndoramin is a discontinued piperidine antiadrenergic drug with the trade names Baratol and Doralese. … It is a selective alpha-1 adrenergic antagonist with no reflex tachycardia and direct myocardial depression action.
Hydroxydione
go.drugbank.com/drugs/DB08956ApprovedWithdrawnHydroxydione (Viadril) is a neuroactive steroid used as a general anesthetic.